Press Releases<< Back
CHF Solutions to Host Webinar Discussing Treatment of Fluid Overload in Pediatric Patients
Fluid overload is associated with significant increases in morbidity and mortality in pediatric patients. Maintaining fluid balance while assuring hemodynamic stability in critically ill pediatric patients is crucial to reduce the risk of morbidity and mortality. Diuretics and traditional CRRT devices are not always optimal for pediatric patients with fluid overload.
The Aquadex SmartFlow™ System is used to remove excess fluid precisely and gently in a way that maintains stable blood flow in the heart and vessels (hemodynamic stability). A retrospective, multi-center study of 32 critically ill pediatric patients showed that 97% of these patients survived to the end of therapy when their fluid overload was treated with the Aquadex system.1
“Ultrafiltration therapy is an effective solution for the underserved pediatric patients suffering from fluid overload,” said
Register to participate in this webinar:
About the Aquadex SmartFlow System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements about the treatment of fluid overload in pediatric patients. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our commercial strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the
Claudia Napal DraytonChief Financial Officer, CHF Solutions, Inc.952-345-4205 email@example.com MEDIA: Jessica StebingHealth+Commerce 260-336-6202 firstname.lastname@example.org
Source: CHF Solutions, Inc.